Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Brown Ripin

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Opinion in HIV and AIDS|October 9, 2013
Treatment optimization: an outline for future successCharles Flexner, Ben Plumley, David H Brown Ripin
The Lancet. Infectious Diseases|June 30, 2012
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statementKeith W Crawford, David H Brown Ripin, Andrew D Levin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?David H Brown Ripin, Kelly Catlin, Linda Lewis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 23, 2011
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countriesCarolyn D Amole, Catherine Brisebois, Shaffiq Essajee, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2019
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority TrialWillem Daniel Francois Venter, Andrew Kambugu, Matthew F Chersich, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Opinion in HIV and AIDS|October 9, 2013
Treatment optimization: an outline for future successCharles Flexner, Ben Plumley, David H Brown Ripin
The Lancet. Infectious Diseases|June 30, 2012
Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statementKeith W Crawford, David H Brown Ripin, Andrew D Levin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?David H Brown Ripin, Kelly Catlin, Linda Lewis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 23, 2011
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countriesCarolyn D Amole, Catherine Brisebois, Shaffiq Essajee, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2019
Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority TrialWillem Daniel Francois Venter, Andrew Kambugu, Matthew F Chersich, et al.
Pageof 1